The impact of advanced glycation end products on bone properties in chronic kidney disease
| Autor: | John G Damrath, Joseph M. Wallace, Sharon M. Moe, Amy Creecy |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Glycation End Products
Advanced Oncology medicine.medical_specialty Bone density 030232 urology & nephrology 030204 cardiovascular system & hematology Bone tissue Article Bone and Bones Fractures Bone 03 medical and health sciences 0302 clinical medicine Bone Density Glycation Internal medicine Internal Medicine medicine Humans In patient Renal Insufficiency Chronic business.industry medicine.disease Increased risk medicine.anatomical_structure Nephrology Material quality business Type I collagen Kidney disease |
| Zdroj: | Curr Opin Nephrol Hypertens |
| ISSN: | 1473-6543 1062-4821 |
| DOI: | 10.1097/mnh.0000000000000713 |
| Popis: | PURPOSE OF REVIEW: Chronic kidney disease (CKD) affects over 15% of Americans and results in an increased risk of skeletal fractures and fracture-related mortality. However, there remain great challenges in estimating fracture risk in CKD patients, as conventional metrics such as bone density assess bone quantity without accounting for the material quality of the bone tissue. The purpose of this review is to highlight the detrimental effects of advanced glycation end products (AGEs) on the structural and mechanical properties of bone, and to demonstrate the importance of including bone quality when assessing fracture risk in CKD patients. RECENT FINDINGS: Increased oxidative stress and inflammation drive the production of AGEs in CKD patients which form non-enzymatic crosslinks between type I collagen fibrils in the bone matrix. Non-enzymatic crosslinks stiffen and embrittle the bone, reducing its ability to absorb energy and resist fracture. Clinical measurement of AGEs is typically indirect and fails to distinguish the identity and properties of the various AGEs. SUMMARY: Accounting for the impact of AGEs on the skeleton in CKD patients may improve our estimation of overall bone quality, fracture risk, and treatments to improve both bone quantity and quality by reducing AGEs in patients with CKD merit investigation in order to improve our understanding of the etiology of increased fracture risk. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|